The Role of the Pentose Phosphate Pathway in Diabetes and Cancer

Tongxin Ge1, Jiawen Yang1, Shihui Zhou1, Yuchen Wang1, Yakui Li1, Xuemei Tong1
1Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Patra, 2014, The pentose phosphate pathway and cancer, Trends Biochem Sci, 39, 347, 10.1016/j.tibs.2014.06.005

Wamelink, 2008, The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review, J Inherit Metab Dis, 31, 703, 10.1007/s10545-008-1015-6

Yen, 2020, Impaired inflammasome activation and bacterial clearance in G6PD deficiency due to defective NOX/p38 MAPK/AP-1 redox signaling, Redox Biol, 28, 101363, 10.1016/j.redox.2019.101363

Bradshaw, 2019, Cytoplasmic and mitochondrial NADPH-coupled redox systems in the regulation of aging, Nutrients., 11, 504, 10.3390/nu11030504

Stincone, 2015, The return of metabolism: biochemistry and physiology of the pentose phosphate pathway, Biol Rev Camb Philos Soc, 90, 927, 10.1111/brv.12140

Zheng, 2018, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, Nat Rev Endocrinol, 14, 88, 10.1038/nrendo.2017.151

Czech, 2017, Insulin action and resistance in obesity and type 2 diabetes, Nat Med., 23, 804, 10.1038/nm.4350

Zatterale, 2020, Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes, Front Physiol, 10, 1607, 10.3389/fphys.2019.01607

Saltiel, 2017, Inflammatory mechanisms linking obesity and metabolic disease, J Clin Invest, 127, 1, 10.1172/JCI92035

Viola, 2019, The metabolic signature of macrophage responses, Front Immunol, 10, 1462, 10.3389/fimmu.2019.01462

Donath, 2019, Targeting innate immune mediators in type 1 and type 2 diabetes, Nat Rev Immunol., 19, 734, 10.1038/s41577-019-0213-9

Lackey, 2016, Regulation of metabolism by the innate immune system, Nat Rev Endocrinol, 12, 15, 10.1038/nrendo.2015.189

Reilly, 2017, Adapting to obesity with adipose tissue inflammation, Nat Rev Endocrinol, 13, 633, 10.1038/nrendo.2017.90

Kim, 2015, Mechanism of ER stress and inflammation for hepatic insulin resistance in obesity, Ann Nutr Metab, 67, 218, 10.1159/000440905

Petersen, 2007, The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome, Proc Natl Acad Sci USA, 104, 12587, 10.1073/pnas.0705408104

Guilherme, 2008, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes, Nat Rev Mol Cell Biol, 9, 367, 10.1038/nrm2391

Perry, 2015, Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes, Cell, 160, 745, 10.1016/j.cell.2015.01.012

Li, 2013, Adipokines and hepatic insulin resistance, J Diabetes Res, 2013, 170532, 10.1155/2013/170532

Manne, 2018, Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Clin Liver Dis, 22, 23, 10.1016/j.cld.2017.08.007

Gerber, 2017, The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus, Antioxid Redox Signal, 26, 501, 10.1089/ars.2016.6755

Lytrivi, 2020, Recent insights into mechanisms of β-cell lipo- and glucolipotoxicity in type 2 diabetes, J Mol Biol, 432, 1514, 10.1016/j.jmb.2019.09.016

Ham, 2013, Macrophage glucose-6-phosphate dehydrogenase stimulates proinflammatory responses with oxidative stress, Mol Cell Biol, 33, 2425, 10.1128/MCB.01260-12

Park, 2017, The role of glucose-6-phosphate dehydrogenase in adipose tissue inflammation in obesity, Adipocyte, 6, 147, 10.1080/21623945.2017.1288321

Tian, 2020, Transketolase deficiency in adipose tissues protects mice from diet-induced obesity by promoting lipolysis, Diabetes, 10.2337/db19-1087

Jin, 2018, Pentose phosphate pathway activity parallels lipogenesis but not antioxidant processes in rat liver, Am J Physiol Endocrinol Metab, 314, E543, 10.1152/ajpendo.00342.2017

Roumans, 2020, Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance, Nat Commun, 11, 1891, 10.1038/s41467-020-15684-0

Gupte, 2009, Synergistic activation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase by Src kinase elevates superoxide in type 2 diabetic, Zucker fa/fa, rat liver, Free Radical Biol Med, 47, 219, 10.1016/j.freeradbiomed.2009.01.028

Lee, 2006, PPARdelta regulates glucose metabolism and insulin sensitivity, Proc Natl Acad Sci USA, 103, 3444, 10.1073/pnas.0511253103

Lee-Young, 2016, Glucose-6-phosphate dehydrogenase contributes to the regulation of glucose uptake in skeletal muscle, Mol Metab, 5, 1083, 10.1016/j.molmet.2016.09.002

Summermatter, 2010, Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) promotes skeletal muscle lipid refueling in vivo by activating de novo lipogenesis and the pentose phosphate pathway, J Bio Chem, 285, 32793, 10.1074/jbc.M110.145995

Summermatter, 2013, PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner, Diabetes, 62, 85, 10.2337/db12-0291

O'Neill, 2016, A guide to immunometabolism for immunologists, Nat Rev Immunol, 16, 553, 10.1038/nri.2016.70

Haschemi, 2012, The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism, Cell Metab, 15, 813, 10.1016/j.cmet.2012.04.023

Nagy, 2015, Time and demand are two critical dimensions of immunometabolism: the process of macrophage activation and the pentose phosphate pathway, Front Immunol, 6, 164, 10.3389/fimmu.2015.00164

Kalwat, 2017, Mechanisms of the amplifying pathway of insulin secretion in the beta cell, Pharmacol Ther, 179, 17, 10.1016/j.pharmthera.2017.05.003

Ferdaoussi, 2015, Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells, J Clin Invest, 125, 3847, 10.1172/JCI82498

Monte Alegre, 1991, Insulin secretion in patients deficient in glucose-6-phosphate dehydrogenase, Horm Metab Res, 23, 171, 10.1055/s-2007-1003644

Spegel, 2013, Time-resolved metabolomics analysis of beta-cells implicates the pentose phosphate pathway in the control of insulin release, Biochem J, 450, 595, 10.1042/BJ20121349

Zhang, 2010, High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis, Faseb J, 24, 1497, 10.1096/fj.09-136572

Lee, 2011, G6PD up-regulation promotes pancreatic beta-cell dysfunction, Endocrinology, 152, 793, 10.1210/en.2010-0606

Riganti, 2012, The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate, Free Radic Biol Med, 53, 421, 10.1016/j.freeradbiomed.2012.05.006

Giacco, 2010, Oxidative stress and diabetic complications, Circulation Res, 107, 1058, 10.1161/CIRCRESAHA.110.223545

Xu, 2005, Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA. which contributes to oxidative stress in rat kidney cortex, Am J Physiol Renal Physiol, 289, F1040, 10.1152/ajprenal.00076.2005

Wang, 2019, High glucose-induced ubiquitination of G6PD leads to the injury of podocytes, Faseb J, 33, 6296, 10.1096/fj.201801921R

Stanton, 2012, Glucose-6-phosphate dehydrogenase, NADPH and cell survival, IUBMB Life, 64, 362, 10.1002/iub.1017

Knapp, 2019, Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy, Acta Pharmacol Sin, 40, 1, 10.1038/s41401-018-0042-6

Rabbani, 2011, Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy, Diabetes Obes Metab, 13, 577, 10.1111/j.1463-1326.2011.01384.x

Maguire, 2018, The role of thiamine dependent enzymes in obesity and obesity related chronic disease states: a systematic review, Clin Nutr ESPEN, 25, 8, 10.1016/j.clnesp.2018.02.007

Babaei-Jadidi, 2003, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine, Diabetes, 52, 2110, 10.2337/diabetes.52.8.2110

Rabbani, 2009, High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study, Diabetologia, 52, 208, 10.1007/s00125-008-1224-4

Hammes, 2003, Brownlee. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy, Nat Med, 9, 294, 10.1038/nm834

Katare, 2010, Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway, Circ Heart Fail, 3, 294, 10.1161/CIRCHEARTFAILURE.109.903450

Gadau, 2006, Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis, Diabetologia, 49, 405, 10.1007/s00125-005-0103-5

Alkhalaf, 2010, A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy, Diabetes Care, 33, 1598, 10.2337/dc09-2241

Fraser, 2012, The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial, Diabetes Care, 35, 1095, 10.2337/dc11-1895

Du, 2013, TAp73 enhances the pentose phosphate pathway and supports cell proliferation, Nat Cell Biol, 15, 991, 10.1038/ncb2789

Jiang, 2013, A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation, Cell Cycle, 12, 3720, 10.4161/cc.27267

Mitsuishi, 2012, Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, Cancer Cell, 22, 66, 10.1016/j.ccr.2012.05.016

Rao, 2015, O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth, Nat Commun, 6, 8468, 10.1038/ncomms9468

Yin, 2017, ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway, J Exp Clin Cancer Res, 36, 166, 10.1186/s13046-017-0637-7

Hong, 2014, PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis, Gut, 63, 1635, 10.1136/gutjnl-2013-305302

Kong, 2016, BAG3 elevation inhibits cell proliferation via direct interaction with G6PD in hepatocellular carcinomas, Oncotarget, 7, 700, 10.18632/oncotarget.6396

Wu, 2018, Transcription factor YY1 promotes cell proliferation by directly activating the pentose phosphate pathway, Cancer Res, 78, 4549, 10.1158/0008-5472.CAN-17-4047

Jiang, 2011, p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase, Nat Cell Biol, 13, 310, 10.1038/ncb2172

Duvel, 2010, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol Cell, 39, 171, 10.1016/j.molcel.2010.06.022

Poulain, 2017, Leukemia, 31, 2326, 10.1038/leu.2017.81

Xu, 2016, SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation, Sci Rep, 6, 32734, 10.1038/srep32734

Wang, 2016, Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes, Cancer Lett, 378, 69, 10.1016/j.canlet.2016.05.004

TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism1880 ChengJ HuangY ZhangX YuY WuS JiaoJ 10.1038/s41467-020-15819-332312982Nat Commun112020

Ma, 2017, Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway, Nat Commun, 8, 1506, 10.1038/s41467-017-01647-5

Sheng, 2019, YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation, Carcinogenesis., 10.1093/carcin/bgz152

Shan, 2014, Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth, Mol Cell, 55, 552, 10.1016/j.molcel.2014.06.020

Liu, 2019, Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance, Nat Commun, 10, 991, 10.1038/s41467-019-08921-8

Ying, 2012, Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism, Cell, 149, 656, 10.1016/j.cell.2012.01.058

Xu, 2016, Transketolase counteracts oxidative stress to drive cancer development, Proc Natl Acad Sci USA, 113, E725, 10.1073/pnas.1508779113

Dasgupta, 2018, Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer, Nature, 556, 249, 10.1038/s41586-018-0018-1

Zhao, 2010, Thompson. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming, Oncogene, 29, 2962, 10.1038/onc.2010.67

Shukla, 2017, Singh. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer, Cancer Cell, 32, 71, 10.1016/j.ccell.2017.06.004

Wang, 2015, Glucose-6-phosphate dehydrogenase expression is correlated with poor clinical prognosis in esophageal squamous cell carcinoma, Eur J Surg Oncol, 41, 1293, 10.1016/j.ejso.2015.08.155

Wang, 2012, Overexpression of G6PD is associated with poor clinical outcome in gastric cancer, Tumour Biol, 33, 95, 10.1007/s13277-011-0251-9

Zhang, 2017, PAK4 regulates G6PD activity by p53 degradation involving colon cancer cell growth, Cell Death Dis, 8, e2820, 10.1038/cddis.2017.85

Chen, 2018, Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro, Int J Oncol, 53, 1703, 10.3892/ijo.2018.4501

Benito, 2017, Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome, Oncotarget, 8, 106693, 10.18632/oncotarget.21601

Ding, 2015, iTRAQ-based quantitative proteomic analysis of cervical cancer, Int J Oncol, 46, 1748, 10.3892/ijo.2015.2859

Zhang, 2017, G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3, Oncotarget, 8, 109043, 10.18632/oncotarget.22566

Nagashio, 2019, Prognostic significance of G6PD expression and localization in lung adenocarcinoma, Biochim Biophys Acta Proteins Proteom, 1867, 38, 10.1016/j.bbapap.2018.05.005

Bensaad, 2006, TIGAR. a p53-inducible regulator of glycolysis and apoptosis, Cell, 126, 107, 10.1016/j.cell.2006.05.036

Kowalik, 2016, Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis, Oncotarget, 7, 32375, 10.18632/oncotarget.8632

Cha, 2017, Differential site-based expression of pentose phosphate pathway-related proteins among breast cancer metastases, Dis Markers, 2017, 7062517, 10.1155/2017/7062517

Lin, 2015, 6-Phosphogluconate dehydrogenase links oxidative PPP. lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling, Nat Cell Biol, 17, 1484, 10.1038/ncb3255

Hitosugi, 2012, Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth, Cancer Cell, 22, 585, 10.1016/j.ccr.2012.09.020

Chan, 2013, 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met, Biochem Biophys Res Commun, 439, 247, 10.1016/j.bbrc.2013.08.048

McDonald, 2017, Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis, Nat Genet, 49, 367, 10.1038/ng.3753

Chen, 2019, 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming, Biomed Pharmacother, 111, 1353, 10.1016/j.biopha.2019.01.028

Guo, 2019, Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1, Clin Transl Oncol, 21, 404, 10.1007/s12094-018-1937-x

Giusti, 2008, Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers, J Proteome Res, 7, 4079, 10.1021/pr8000404

Yang, 2018, Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation, Clin Transl Oncol, 20, 1145, 10.1007/s12094-018-1833-4

Zheng, 2017, Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer, Front Pharmacol, 8, 421, 10.3389/fphar.2017.00421

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming6763950 BhanotH WeisbergEL ReddyMM NonamiA NeubergD StoneRM 10.18632/oncotarget.1879728978059Oncotarget82017

Ciou, 2015, Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling, Int J Cancer, 137, 104, 10.1002/ijc.29361

Chou, 2019, Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and beta-catenin pathways, Carcinogenesis, 40, 461, 10.1093/carcin/bgy155

Chou, 2018, Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating beta-catenin via a novel C-terminal domain, PLoS Biol, 16, e2003714, 10.1371/journal.pbio.2003714

Qiu, 2015, MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells, Gastroenterology, 149, 1587, 10.1053/j.gastro.2015.07.050

Liu, 2010, Fructose induces transketolase flux to promote pancreatic cancer growth, Cancer Res, 70, 6368, 10.1158/0008-5472.CAN-09-4615

Kochetov, 2014, Structure and functioning mechanism of transketolase, Biochim Biophys Acta, 1844, 1608, 10.1016/j.bbapap.2014.06.003

Vizan, 2009, Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29, Int J Cancer, 124, 2789, 10.1002/ijc.24262

Xu, 2009, Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells, Int J Cancer, 124, 1330, 10.1002/ijc.24078

Li, 2019, Transketolase deficiency protects the liver from DNA damage by increasing levels of ribose 5-phosphate and nucleotides, Cancer Res, 79, 3689, 10.1158/0008-5472.CAN-18-3776

Qin, 2019, Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner, J Exp Clin Cancer Res, 38, 154, 10.1186/s13046-019-1131-1

Kocevar, 2012, Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers, World J Gastroenterol, 18, 1216, 10.3748/wjg.v18.i11.1216

Wang, 2011, Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples, Cancer Lett, 313, 154, 10.1016/j.canlet.2011.08.031

Ding, 2018, Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers, Nat Commun, 9, 4274, 10.1038/s41467-018-06651-x

Hanczko, 2009, Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine, J Clin Invest, 119, 1546, 10.1172/JCI35722

Fan, 2014, Quantitative flux analysis reveals folate-dependent NADPH production, Nature, 510, 298, 10.1038/nature13236

Traverso, 2013, Role of glutathione in cancer progression and chemoresistance, Oxid Med Cell Longev, 2013, 972913, 10.1155/2013/972913

Assi, 2017, The differential role of reactive oxygen species in early and late stages of cancer, Am J Physiol Regul Integr Comp Physiol., 313, R646, 10.1152/ajpregu.00247.2017

Forrester, 2018, Reactive oxygen species in metabolic and inflammatory signaling, Circulation Res., 122, 877, 10.1161/CIRCRESAHA.117.311401

Newsholme, 2016, Molecular mechanisms of ROS production and oxidative stress in diabetes, Biochem J, 473, 4527, 10.1042/BCJ20160503C

Malaguarnera, 2011, The insulin receptor: a new target for cancer therapy, Front Endocrinol., 2, 93, 10.3389/fendo.2011.00093

Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat Rev Cancer., 8, 915, 10.1038/nrc2536

Andersen, 2017, Diabetes, pancreatogenic diabetes, and pancreatic cancer, Diabetes, 66, 1103, 10.2337/db16-1477

Poh, 2018, Targeting macrophages in cancer: from bench to bedside, Front Oncol, 8, 49, 10.3389/fonc.2018.00049

Cassetta, 2018, Targeting macrophages: therapeutic approaches in cancer, Nat Rev Drug Discov, 17, 887, 10.1038/nrd.2018.169